Femasys crossed the midpoint of 2026 with two stories running at once, and the market is pricing only the weaker one. The commercial story is a small revenue base in transition: total sales fell nineteen percent in the quarter as international demand for its older FemVue device faded, while the company shifts commercial energy to FemaSeed, its newer infertility treatment. The capital story is more urgent: cash of one point four million dollars against an accumulated deficit of one hundred forty-nine million dollars means the company is financing a pivotal trial and a product launch on a runway measured in quarters, not years.
The tension that matters is between the clinical program and the balance sheet. FemBloc, the permanent birth control candidate that is the company's largest addressable market, is in a pivotal trial, and research and development spending rose thirty-eight percent as the company moved development inventory into commercial readiness. That spending is the right call for the long-term value, but it is consuming cash faster than a three-hundred-thirty-thousand-dollar quarterly sales line can fund, and the company is leaning on an at-the-market facility and a structured purchase agreement to bridge the gap. The share count has roughly tripled as those instruments convert, which is the quiet cost of staying alive.
The question the next two quarters resolve is whether the FemaSeed commercial ramp and the FemBloc trial milestone arrive before the cash runway does. The company ended the quarter with one point four million dollars in cash and roughly nine point four million dollars available on its at-the-market facility, and the next financing event, whether a draw, a raise, or a strategic transaction, is the clock the equity is trading against.